BIOVF News and Press, Swedish Orphan Biovit Ord From 07/22/21

Swedish Orphan Biovitrum AB (publ) Q2 2022 Earnings Conference Call July 21, 2021 07:00 ET Company Participants Guido Oelkers - Chief Executive Officer Ravi Rao - Head, Research & Development Henrik Stenqvist - Chief Financial Officer Conference Call Participants Eun Yang - Jefferies Chri...

The following slide deck was published by Swedish Orphan Biovitrum AB (publ) in conjunction with their 2021 Q2 earnings call. For further details see: Swedish Orphan Biovitrum AB (publ) 2021 Q2 - Results - Earnings Call Presentation

Swedish Orphan Biovitrum AB (BIOVF): Q2 GAAP EPS of SEK0.90.Revenue of SEK3.21B (+4.6% Y/Y)Press Release For further details see: Swedish Orphan Biovitrum AB reports Q2 results

Apellis Pharmaceuticals (APLS) and Swedish Orphan Biovitrum AB (BIOVF) report positive top-line results from the Phase 3 PRINCE study evaluating the efficacy and safety of Empaveli (pegcetacoplan) in adults with paroxysmal nocturnal hemoglobinuria ((PNH)) who are treatment naïve. At week...

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q1 2021 Earnings Conference Call May 4, 2021 7:00 AM ET Company Participants Guido Oelkers - CEO Ravi Rao - Head, R&D Henrik Stenqvist - CFO Conference Call Participants Eun Yang - Jefferies Erik Hultgard - Carnegie Christopher Uhde - SEB Peter S...

Swedish Orphan Biovitrum AB (BIOVF): Q1 GAAP EPS of SEK2.36.Revenue of SEK3.66B (-21.1% Y/Y)Press Release For further details see: Swedish Orphan Biovitrum AB reports Q1 results

Full phase 3 data for Apellis Pharmaceuticals' (APLS) paroxysmal nocturnal hemoglobinuria (PNH) drug candidate pegcetacoplan indicates it is superior to Alexion Pharmaceuticals' (ALXN) Soliris (eculizumab).The data was published in The New England Journal of Medicine.Full results from the PEG...

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2020 Earnings Conference Call February 18, 2021, 07:00 ET Company Participants Guido Oelkers - CEO & President Ravi Rao - Head, Research & Development & Chief Medical Officer Henrik Stenqvist - CFO Conference Call Participants Christop...

The following slide deck was published by Swedish Orphan Biovitrum AB (publ) in conjunction with their 2020 Q4 earnings call. For further details see: Swedish Orphan Biovitrum AB (publ) 2020 Q4 - Results - Earnings Call Presentation

The drug portfolio of Alexion Pharmaceuticals (ALXN) is led by C5-inhibitors: Ultomiris (ALXN1210/ravulizumab-cwvz) and Soliris (eculizumab). In the wake of its proposed merger with AstraZeneca (AZN), even clinical-stage biopharmaceutical companies focused on complement-mediated therapies hav...